Abstract
RNA interference (RNAi) has emerged as a potent biological mechanism for regulating gene expression, with significant therapeutic applications. This presentation showcases Global Nucleotide Acid Therapy/Novo Nordisk's cutting-edge GalXC and GalXC-plus platforms, which are at the forefront of RNAi drug development. The presentation will outline a comprehensive, multi-stage screening process for RNAi therapeutic candidates, starting from computational design to in vitro and in vivo testing, demonstrating the precision and effectiveness of RNAi therapeutics across various diseases.
BioSketch
Dr. Jihye Park currently serves as an Associate Director in the Global Nucleic Acid Therapy at Novo Nordisk. Dr. Park's expertise in oligonucleotide biology and drug discovery has been instrumental in leading her teams through successful in vitro and in vivo screenings, which have resulted in multiple Investigational New Drug (IND) candidates. Her contributions include leading the design and execution of structure-activity relationship (SAR) studies, which have advanced the company’s siRNA platforms. Prior to her current role, Dr. Park honed her skills at the Beth Israel Deaconess Medical Center as a Postdoctoral Research Fellow in Pathology, where she characterized the function of Lig4 in the immune system. Dr. Park received her Ph.D. in Life and Pharmaceutical Sciences from Ewha Womans University in Seoul, South Korea, where she demonstrated the direct role of chromatin remodeling in double-strand break repair, earning her the 'Brain Korea (B.K.) 21' Award for Outstanding Graduate Student Research. Dr. Park's educational background, combined with her extensive professional experience, has established her as a leader in the field of RNAi and drug discovery.